Irvine Scientific has expanded its line of products supporting stem and immunological cell therapies with the introduction of PRIME-XV Haematopoietic Cell Basal Medium. This new formulation follows other media in the PRIME-XV range as it is another serum-free, xeno-free basal medium that specifically supports robust expansion of haematopoietic progenitors while maintaining their multipotency, or functional properties needed for cell-based therapies.
Haematopoietic stem and progenitor cells (HSPCs) give rise to all other blood cells, and therefore have therapeutic potential for the treatment of cancers such as leukaemia and lymphoma, and non-malignant diseases such as sickle cell anaemia or immune-related disorders. However, to be effective, there must be sufficient numbers of HSPCs that retain their progenitor cell properties, including self-renewal and multipotency, to provide successful therapies.
Haematopoietic stem and progenitor cells are often obtained from the blood or bone marrow of donors and are rare (only 1 in 100,000 in peripheral blood cells, and 1 in 10,000 in bone marrow). With numbers of cells in the 100s of millions required for therapy, the challenge has been to obtain sufficient numbers of HSPCs that maintain their progenitor cell properties to differentiate and mature into the various haematopoietic lineage cells needed for therapies.
“In ex vivo culture, HSPCs tend to differentiate spontaneously over time, making it difficult to obtain large numbers of multipotent cells,” explained Dr Jessie Ni (Irvine Scientific). “When supplemented with the appropriate cytokines, PRIME-XV Haematopoietic Cell Basal Medium is formulated to support robust expansion of cell numbers while maintaining high percentages of multipotent haematopoietic progenitor cells.”
Its serum-free, xeno-free formula reduces the risks of contamination associated with media containing serum or non-human, animal-derived components. PRIME-XV Haematopoietic Cell Basal Medium is manufactured using stringent raw material qualification and under current Good Manufacturing Practices (cGMP) for consistency, reliability and to make the move from research towards clinical applications.
